



Public Alert Notice on Unauthorized NERO-B (VB1+VB6+VB12 Tablet; Thiamine 10mg+Pyridoxine Hydrochloride 3mg+Cyanocobalamin 15mcg mg) tablet; Medical Product Alert 09/2025

Alert Summary

The Ethiopian Food and Drug Authority (EFDA) is mandated under Article 38 of the Food and Medicine Administration Proclamation No. 1112/2019 to conduct periodic monitoring of the safety, quality, and efficacy of medicines through surveillance.

The Authority has accepted a product quality defect report concerning NERO-B tablets (Vitamin B1 + B6 + B12; Thiamine 10 mg, Pyridoxine Hydrochloride 3 mg, and Cyanocobalamin 15 mcg). In response, the Authority assessed the complaint, conducted an investigation, and carried out market surveillance to verify the product's presence in the market. The investigation revealed that the product unauthorized for marketing by the Ethiopian Food and Drug Authority.

Brief Description of the Product

- **Product Name: NERO-B (Vitamin B1 + B6 + B12; Thiamine 10 mg, Pyridoxine Hydrochloride 3 mg, Cyanocobalamin 15 mcg) Tablet**
- **Batch Number: 231001SZU**
- **Manufacture Date: 13/2023**
- **Expiry Date: 13/2026**
- **Manufacturer: Not stated on the secondary packaging**
- **Supplier: Anhui Medipharm Co. Ltd.**

Risk Summary

These unauthorized products are considered unsafe and may pose significant health risks, particularly for patients experiencing nerve damage, vitamin deficiencies, or metabolic disorders. The unauthorized NERO-B tablet lacks proven efficacy and should not be used for the treatment of conditions such as neuropathy, vitamin B deficiencies, nerve repair, pain management, or general fatigue and weakness.

How to identify these Falsified products

The unregistered product was identified by comparing it with other authorized Vitamin B complex tablets registered by the Ethiopian Food and Drug Authority.

Target Audiences

Advice to Healthcare Professionals

The Authority intends to alert healthcare providers about the need to identify and remove unauthorized and substandard medicinal products from circulation and use, in order to prevent harm to patients. Patients are also strongly advised to refrain from using the unauthorized NERO-B tablets.

Advice to Regional Regulatory Bodies

The authority also intends to alert the regional regulatory authority to monitor the circulation and use of unauthorized and substandard product.

Public Advice

If you are in possession of this unauthorized and substandard product, please do not use it. If you or anyone you know has used this product or experienced any adverse reaction following its use, you are advised to seek immediate medical attention from a qualified healthcare professional.

Report Adverse Events

The EFDA encourage members of the public and health care provider to report all suspicious, substandard and falsified medicinal products to the Ethiopia Food and Drug Authority through, ADE reporting form, Med safety mobile apps available at play store for androids and app store for iPhone, E-reporting available on EFDA website (www.efda.gov.et), through email pharmacovigilance@efda.gov.et and Toll-free number 8482.

Secondary Package of the unregistered product

